Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sept 18 (Reuters) — SANDOZ GROUP AG: Sandoz Announces Collaboration With Mabxience To Expand Patient Access To Life-enhancing Biosimilar Medicines Agrees Emicizumab Biosimilar In $5.70 Billion Market; First Haemophilia Biosimilar In Pipeline Biosimilar Pipeline Expands To 40 Assets Following Agreement With Mabxience So
Sandoz signed a licensing, development, manufacturing, commercialisation deal with mAbxience for a proposed emicizumab biosimilar. Agreement gives Sandoz exclusive global commercialisation rights, excluding Argentina, Uruguay, Paraguay; mAbxience will handle development, manufacturing. Targets Hemlibra reference market